Viridian Therapeutics (VRDN) Stock Price, News & Analysis

Company Overview

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $14.98 to $15.94
• 50-Day Range: $12.03 to $16.09
• 52-Week Range: $9.90 to $27.20
• Volume: 396,622 shs
• Average Volume: 1.15 million shs
• Market Capitalization: $1.27 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.56
• Consensus Rating: Moderate Buy

Viridian Therapeutics Stock Analysis - MarketRank™

Viridian Therapeutics scored higher than 26% of companies evaluated by MarketBeat, and ranked 740th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Viridian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Viridian Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Viridian Therapeutics are expected to decrease in the coming year, from ($4.03) to ($4.31) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Viridian Therapeutics is -4.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Viridian Therapeutics is -4.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Viridian Therapeutics has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.12% of the float of Viridian Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Viridian Therapeutics has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.

Change versus previous month

Short interest in Viridian Therapeutics has recently increased by 5.98%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Viridian Therapeutics does not currently pay a dividend.

Dividend Growth

Viridian Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.12% of the float of Viridian Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Viridian Therapeutics has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.

Change versus previous month

Short interest in Viridian Therapeutics has recently increased by 5.98%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for VRDN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Viridian Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.58% of the stock of Viridian Therapeutics is held by insiders.

VRDN Stock Analysis - Frequently Asked Questions

How have VRDN shares performed this year?

Viridian Therapeutics' stock was trading at $19.17 at the start of the year. Since then, VRDN stock has decreased by 18.7% and is now trading at $15.5850.
View the best growth stocks for 2025 here.

How were Viridian Therapeutics' earnings last quarter?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) posted its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.87) earnings per share for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. Viridian Therapeutics's revenue for the quarter was up .0% on a year-over-year basis.

How do I buy shares of Viridian Therapeutics?

Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Viridian Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Viridian Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/03/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:VRDN
• CIK: 1590750
• Web: www.viridiantherapeutics.com
• Phone: (617) 272-4600
• Fax: 760-537-4101
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $37.56
• High Stock Price Target: $61.00
• Low Stock Price Target: $27.00
• Potential Upside/Downside: +141.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$269.95 million
• Net Margins: -102,092.39%
• Pretax Margin: -102,092.39%
• Return on Equity: -70.61%
• Return on Assets: -44.67%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 19.49
• Quick Ratio: 19.49

Sales & Book Value

• Annual Sales: $300 thousand
• Price / Sales: 4,238.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.09 per share
• Price / Book: 2.56

Miscellaneous

• Outstanding Shares: 81,590,000
• Free Float: 80,303,000
• Market Cap: $1.27 billion
• Optionable: Optionable
• Beta: 0.39